SVB Securities analyst Andrew Berens assigned a Buy rating to Zymeworks (ZYME – Research Report) on May 5 and set a price target of $18.00. The company's shares closed last Friday at $5.98, close to its 52-week low of $4.56. According to TipRanks.com, Berens has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.5% and a 36.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $21.50, which is a 233.3% upside from current levels.
https://www.tipranks.com/news/blurbs/svb-securities-thinks-zymeworks-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Zymeworks Charts.
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Zymeworks Charts.